Uncertainty in Decision Models Analyzing Cost-Effectiveness

Markov chains have been increasingly used to describe the progression of a medical condition through distinct health states.2 Markov chains are described by the transition matrix that contains the probabilities that a subject moves from one state to another state by the end of a cycle (e g., a month or a year). Because this is a matrix of probabilities, the path that a subject follows is stochastic or random. This inherent variability, termed sampling uncertainty by Hunink et al., is what makes the Markov

[1]  D. A. Williams,et al.  The analysis of binary responses from toxicological experiments involving reproduction and teratogenicity. , 1975, Biometrics.

[2]  A A Stinnett,et al.  Net Health Benefits , 1998, Medical decision making : an international journal of the Society for Medical Decision Making.

[3]  J R Beck,et al.  Markov Models in Medical Decision Making , 1993, Medical decision making : an international journal of the Society for Medical Decision Making.

[4]  B A Craig,et al.  Estimating AIDS-free survival in a severely immunosuppressed asymptomatic HIV-infected population in the era of antiretroviral triple combination therapy. Swiss HIV Cohort Study. , 1999, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[5]  M C Weinstein,et al.  Uncertainty in Decision Models Analyzing Cost-Effectiveness , 1998, Medical decision making : an international journal of the Society for Medical Decision Making.

[6]  M J Al,et al.  Costs, effects and C/E-ratios alongside a clinical trial. , 1994, Health economics.

[7]  Williams Da,et al.  The analysis of binary responses from toxicological experiments involving reproduction and teratogenicity. , 1975 .